← All Signals

🏥 FDA: Rising Pharma Holding, Inc. — Class II

healthcarebearishSource: FDA
80%Confidence
0Views
FDASource
2026-03-21Date

Summary

Rising Pharma's Temozolomide Capsules recall due to stability testing failures indicates potential quality issues with this important oncology medication manufactured in Taiwan. This could disrupt cancer treatment regimens and prompt increased testing requirements for Rising's other products.

Actionable: Review stability data for all Rising Pharmaceuticals products and establish contingency plans for critical oncology medications.

AI Confidence: 80%

Data Points

firmRising Pharma Holding, Inc.
classificationClass II
statusOngoing
distributionNationwide within the U.S
productProduct label: Temozolomide Capsules, 5mg, packaged in 5-capsule bottles, Rx only, Manufactured for: Rising Pharmaceuticals, Inc., Allendale, NJ 07401

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now